With PAS-X on the Way to an Integrated Biopharmaceutical e-Plant
14 November 2012 - PAS-X successfully went live at Merck Serono's production plant in Vevey, Switzerland. Werum's worldwide leading Manufacturing Execution System for the pharmaceuticals and biotechnology industry manages and controls the manufacturing of the cancer treatment drug Erbitux®, which Merck Serono produces at this site.
As the central IT platform, PAS-X integrates the ERP and two DCS systems, replaces paper-based documentation and ensures efficient, seamless batch and process data flows - from process development to commercial production. As a result, Merck Serono has moved a giant step closer to achieving its goal of setting up an integrated biopharmaceutical electronic plant at Vevey.
"Our biopharmaceutical production benefits considerably from Werum's PAS-X MES," said Nicolas-Martin Clément, e-plant Manager at Merck Serono. "The number of data entry errors has greatly decreased, and with the 'review-by-exception function' we can approve manufacturing records in half the original time. For us, that means a great reduction in the non-value added activities!"
Against the background of this positive experience, Werum has begun with the implementation of PAS-X for another new production system in Vevey - for Rebif®, a drug for treatment of multiple sclerosis. As part of the project, Werum will connect the PAS-X system to the LIMS system and support the perfusion process with new MES functionalities.
In the context of its global MES partnership with Merck Serono, Werum has equipped three production sites with PAS-X up until now: the biotechnology plant in Vevey as well as the pharmaceutical plants in Darmstadt, Germany and Naucalpan, Mexico.